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Since cancer survival rates in general are increasing,
second primary cancers (SPCs) account for an increasing
proportion of the overall cancer burden. In some cancer
registries they account for more than 20% of new diag-
noses1. Contributing factors for SPCs may be multiple,
including iatrogenic adverse effects of chemotherapy or
radiation, increased surveillance and the same causes that
influenced patients’ first cancers, including family history
and environmental causes2–4. Chemotherapy and radia-
tion induce DNA damage which increases the risk of
SPCs, and therapy-associated immunosuppression could
also play a role. Treatment for multiple myeloma (MM)
involves intense chemotherapy and concerns about SPCs
have been raised, particularly relating to the possible
effects of lenalidomide and melphalan5. The impact of
family history was recently shown in survivors of Hodgkin
lymphoma with an excess of lung, colorectal, and breast
cancers in survivors with a family history of these can-
cers6. The potential importance of family history is
emphasized by the fact that about 50% of patients with
first primary cancer have a first-degree relative diagnosed
with some cancer7. This proportion was also high among
patients diagnosed with MM, 61%7. The other cancers in
family members were diverse; including chronic lym-
phocytic leukemia and colorectal and prostate cancers8,9.
In the present study we use the Swedish Family-Cancer
Database, with two goals, first to assess the influence of
family history on the risk of SPC, and second to estimate
the influence of SPC on mortality in MM in family
members7. A family history implies that the type of SPC
(e.g., lung cancer) was the same cancer that was diagnosed
in a parent or sibling (e.g. lung cancer).
Methods
In the Swedish Family-Cancer Database the second
generation ‘offspring’ was defined as individuals born after
1931 and their patents were defined as the parental gen-
eration. Another truncation of data was caused by the
start of cancer registration in Sweden in 1958. The study
included 25,787 MM diagnosed from 1958 to 2015; of
these 5205 were diagnosed in the offspring generation
with a median age at diagnosis of 62 years. Among MM
patients 360 (6.9%) were diagnosed with SPC after a
median follow-up time of 4 years. Among these 360, 246
(68.3%) had a first-degree family history of any cancer.
Relative risks (RRs) were assessed with incidence rate
ratios, estimated with RRs regressed over a fixed effects
generalized Poisson model. RRs for SPC were obtained by
comparing incidence rates for SPC X in MM patients with
rates for first cancer X in the background population of
the database. Family history was defined among parents
and siblings. Familial RRs were estimated by comparing
incidence rates between MM patients diagnosed with
cancer X as SPC and having a family history of cancer X
against those diagnosed with first cancer X in the popu-
lation; the reference rate was the same as above. Sex, age
group, calendar-period, socio-economic status, and resi-
dential areas were treated as potential confounders and
were adjusted for in the regression model. Follow-up
commenced from diagnosis of MM and was terminated
on SPC diagnosis, emigration, death, or end of follow-up
period, i.e. 2015, whichever occurred first. Confidence
intervals were calculated for 5%, 1% and 0.1% level of
significance10. All cancer-related deaths were stratified
into MM, SPC, and other causes, including cancers
defined in death certificates and non-neoplastic causes of
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death. Additive and multiplicative interactions of family
history and risk of SPC were tested as described11.
The study was approved by the Ethical Committee of
Lund University. Analyses are performed in SAS v9.4;
please contact the authors for codes.
Results
Among 5205 MM patients, 360 (6.9%) were diagnosed
with a SPC. Familial SPCs were compared to non-familial
SPCs in Table 1, which lists all SPCs with at least two
cases having the same (concordant) tumor in a parent or
sibling. Ignoring the overlapping impact of more than one
cancer in family, prostate cancer was the major con-
tributor to the family history (20%) followed by colorectal
(14%), breast (10%), bladder (5%), lung cancer, and skin
SCC (4% both). In patients without a family history of
cancer, the risk of SPC was increased for skin cancer
(squamous cell carcinoma, SCC, RR= 2.58) and leukemia
(RR= 4.55). For patients with a family history of cancer,
even though case numbers were low, risks were sig-
nificantly elevated in a trend test for colorectal (RR/
familial= 2.10 vs. RR/non-familial= 1.01), prostate (RR/
familial= 1.60 vs. RR/non-familial= 0.56), and skin SCC
(RR/familial= SCC, 8.82 vs. RR/non-familial= 2.58). The
trend test was of borderline significance (P= 0.061) for
lung cancer (RR/familial= 5.40 vs. RR/non-familial=
1.13). The highest SPC risk was observed for MM patients
with a family history of leukemia (RR= 9.14, only two
cases). Patients with SPC with any familial cancer (N=
246) were 68.3% of all SPCs and the RR was 1.38 vs. 1.13,
respectively (trend test P < 0.001). We tested interactions
of significant family risks and risk of SPC and found a
stronger than additive interaction for skin cancer (P=
0.04).
In order to check for possible skewed patient recruit-
ment based on the multiple applied conditions were
plotted the patient accrual over the study period (Sup-
plementary Figure 1). The diagram shows MM patients
with SPC and with or without family history (246 and 114
patients) plotted by 5-year intervals of MM diagnosis. No
skewing of case accrual was observed.
The total number of deaths by the end of 2015 was 2872
(55.2%) among 5205 patients; and the total number of
deaths among 360 patients with SPC was 228 (60.6%). The
proportion was equally high among 246 patients with
familial SPC, of whom 146 (59.3%) had died.
Kolmogorov–Smirnov test on proportion difference
found no evidence of statistical difference (P > 0.05).
MM was the most common cause of death in patients
without a SPC (83.4%, 2194/2629), with 16.6% of deaths
due to other causes (data not shown). For MM patients
with a SPC, the distribution of causes of death is shown in
Table 2. MM was the leading cause with 38.7% of deaths,
followed by SPC 35.8% and other causes (25.5%); among
other causes the majority of deaths (62.9%) were due to
non-neoplastic causes. The mortality of SPC varied
between second cancer types. For second pancreatic
cancer, all seven patients died of this cancer; more than
half of MM patients died of SPC when it was lung or
nervous system cancer or leukemia. Other causes were
important for CUP as SPC which is due to the practice of
rarely describing CUP as a cause of death12. Among 82
deaths in patients with SPC without a cancer family his-
tory, majority was due to MM (36.6%), closely followed by
SPCs (34.2%). Kolmogorov–Smirnov test found no sig-
nificant difference in proportion contribution by the dif-
ferent causes of death in patients with or without family
history (P > 0.05).
Table 1 Relative risks of SPCs among all multiple myeloma patients stratified over family
Cancer At least 1 FDR with cancer No FDR with cancer Total Trend test P value
N RR 95% CI N RR 95% CI N RR 95% CI
Colorectum 7 2.10 1.00–4.41 27 1.01 0.69–1.47 34 1.13 0.81–1.58 0.033
Lung 3 5.40 1.74–16.75 10 1.13 0.61–2.10 13 1.38 0.80–2.38 0.061
Breast 4 1.13 0.42–3.01 24 0.93 0.62–1.39 28 0.95 0.66–1.38 0.176
Prostate 20 1.60 1.03–2.48 38 0.56 0.41–0.77 58 0.72 0.56–0.93 0.006
Melanoma 2 5.04 1.26–20.14 18 1.46 0.92–2.32 20 1.57 1.01–2.44 0.087
Skin (SCC) 4 8.82 3.31–23.52 31 2.58 1.81–3.67 35 2.81 2.01–3.91 0.029
Leukemia 2 9.14 2.29–36.55 32 4.41 3.11–6.24 34 4.55 3.25–6.37 0.093
All 246 1.38 1.22–1.57 114 1.13 0.94–1.36 360 1.29 1.17–1.43 <0.001
Bold, italics and underline indicate 5%, 1% and 0.1% level of significance
FDR first degree relative, N frequency, RR relative risk, CI confidence interval, SCC squamous cell carcinoma
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Discussion
The novel aspect of this study was the demonstration of
the impact of familial risk on SPCs in MM patients.
Accordingly, as many as 68.3% of SPCs were familial, i.e.,
a parent or sibling of MM patients were diagnosed with
any cancer, moderately higher compared to that of 59.9%
patients without an SPC. For three SPCs with significant
risks, including colorectal, prostate, and skin cancers, the
family members had exactly the same cancer as was the
SPC. It is interesting that in a recent study from this
database the most consistent familial association between
MM and first primary cancers included colorectal and
prostate cancer and leukemia9. This may not be coin-
cidental and shared susceptibility may contribute to these
findings. We showed also that MM patients with SPC
appeared to have moderately worse prognosis (60.6%
dead) compared to all MM patients (55.2% dead), while
family history of SPCs did not increase mortality (59.3%
dead). The limitation of the study was a relatively small
sample size in spite of nation-wide coverage. The reason is
that survival in MM, although improving, is still relatively
poor whereby the time-window for SPCs is narrow13. Due
to the small numbers we did not undertake formal hazard
ratio analysis for survival.
Therapy-related SPCs in MM have mainly been asso-
ciated with acute myeloid leukemia, which has been
increased also in a recent study on German and Swedish
MM patients5,14. The Swedish population of that study
partially overlaps with the present one, where a risk (RR
4.41) of second leukemia was observed in patients lacking
family history. Therapy-related side effects are still con-
sidered relatively weak in MM but the situation may
change when larger patient groups achieve long survival
times5. Family history needs to be considered a possible
confounder in therapy-related studies on SPCs.
In conclusion, 68.3% of MM patients with SPC had a
family history of any cancer. Significantly increased
associations were found for second colorectal, prostate
and skin cancers and family members diagnosed with
these cancers. With continued therapeutic successes in
MM treatment SPCs will be receiving increasing atten-
tion, whereby the contributing role of family history
deserves inquiry into its mechanistic underpinnings.
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Table 2 Causes of death distribution of multiple
myeloma patients diagnosed with SPC
Cancer MM SPCa Other
causes
N % N % N %
UAT 2 50.0 2 50.0 – –
Stomach – – 4 100.0 – –
Colorectum 8 33.3 11 45.8 5 20.9
Anus – – 1 100.0 – –
Liver 2 33.3 3 50.0 1 16.7
Pancreas – – 7 100.0 – –
Lung 3 13.6 15 68.2 4 18.2
Breast 6 42.9 1 7.1 7 50
Cervix – – 1 100.0 – –
Ovary 1 50.0 1 50.0 – –
Prostate 11 42.3 5 19.2 10 38.4
Kidney 3 37.5 3 37.5 2 25
Urinary bladder 5 41.7 3 25.0 4 33.3
Melanoma 7 58.3 3 25.0 2 16.7
Skin (SCC) 16 72.7 1 4.5 5 22.7
Nervous system 3 42.9 4 57.1 – –
NHL 5 45.5 4 36.4 2 18.2
Hodgkin lymphoma – – 1 50.0 1 50
Leukemia 7 24.1 16 55.2 6 20.6
CUP 3 21.4 1 7.1 10 71.4
Totalb 94 38.7 87 35.8 62 25.5
MM multiple myeloma, SPC second primary cancer, UAT upper aerodigestive
tract, SCC squamous cell carcinoma, NHL non-Hodgkin lymphoma, CUP cancer of
unknown primary
aCases noted only when at least one death is observed due to second cancer
bTotal includes all cancers without constraints
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